
Diffuse Parenchymal Lung Disease

Progress in Respiratory Research

Vol. 36

Series Editor *Chris T. Bolliger, Cape Town*

KARGER

Basel · Freiburg · Paris · London · New York ·
Bangalore · Bangkok · Singapore · Tokyo · Sydney

Diffuse Parenchymal Lung Disease

Volume Editors *Ulrich Costabel*, Essen
 Roland M. du Bois, London
 Jim J. Egan, Dublin

144 figures, 15 in color, and 47 tables, 2007

KARGER

Basel · Freiburg · Paris · London · New York ·
Bangalore · Bangkok · Singapore · Tokyo · Sydney

.....

Prof. Dr. Ulrich Costabel

Department of Pneumology and Allergy
Ruhrlandklinik
Tueschener Weg 40
DE-45239 Essen (Germany)

Prof. Dr. Roland M. du Bois

Interstitial Lung Disease Unit & Clinical Genomics Group
Royal Brompton Hospital
Sydney Street
London SW3 6NP (UK)

Dr. Jim J. Egan

The Mater Misericordiae Hospital
University College Dublin
Eccles Street
Dublin 7 (Ireland)

Library of Congress Cataloging-in-Publication Data

Diffuse parenchymal lung disease / volume editors, Ulrich Costabel, Roland M. du Bois, Jim J. Egan.

p. ; cm. – (Progress in respiratory research, ISSN 1422-2140 ; v.

36)

Includes bibliographical references and indexes.

ISBN-13: 978-3-8055-8153-0 (hard cover : alk. paper)

1. Interstitial lung diseases. I. Costabel, Ulrich. II. Du Bois, Roland M.

III. Egan, Jim J. IV. Series.

[DNLM: 1. Lung Diseases. 2. Lung Diseases, Interstitial. W1 PR681DM

v.36 2007 / WF 600 D5695 2007]

RC776.I56D54 2007

616.2'4-dc22

2007010588

Disclaimer. The statements, options and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in

indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 2007 by S. Karger AG,
P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Switzerland on acid-free paper by
Reinhardt Druck, Basel
ISBN 978-3-8055-8153-0, ISSN 1422-2140

Contents

VII Foreword

VIII Preface

General Aspects

2 Classification of Diffuse Parenchymal Lung Disease

Gomez, A.D.; King, T.E., Jr.

11 Diagnostic Approach to Diffuse Parenchymal Lung Disease

Lynch, J.P., III; Weigt, S.S.; Fishbein, M.C.

22 Clinical Evaluation

Yang, S.; Raghu, G.

29 Imaging

Desai, S.R.; Wells, A.U.

44 Diffuse Parenchymal Lung Diseases – Histopathologic Patterns

Chilosi, M.; Murer, B.; Poletti, V.

58 Bronchoalveolar Lavage

Drent, M.; Baughman, R.P.; Meyer, K.C.

Basic Aspects

70 Genetics of Interstitial Lung Disease

du Bois, R.M.

87 Granuloma Formation

Facco, M.; Miorin, M.; Agostini, C.; Semenzato, G.

101 Pathogenesis of Idiopathic Pulmonary Fibrosis

Noble, P.W.

110 Basics of Pulmonary Vasculitis

Cohen Tervaert, J.W.; Damoiseaux, J.G.M.C.

117 Novel Aspects of Treatment for Interstitial Lung Diseases

Behr, J.

Diseases

- 128 Sarcoidosis**
Newman, L.S.; Wasfi, Y.S.
- 139 Hypersensitivity Pneumonitis**
Vogelmeier, C.
- 148 Idiopathic Pulmonary Fibrosis**
Keating, D.T.K.; McCullagh, B.; Egan, J.J.
- 160 Nonspecific Interstitial Pneumonia**
Flaherty, K.R.; Martinez, F.J.
- 175 Diseases: Other Entities of the Idiopathic Interstitial Pneumonias**
Collard, H.R.
- 185 Pulmonary Fibrosis in Collagen Vascular Disease**
Hoyles, R.K.; Wells, A.U.
- 196 Pulmonary Vasculitis**
Lynch, J.P., III; Fishbein, M.C.; White, E.S.
- 212 Drug-Induced and Iatrogenic Infiltrative Lung Disease**
Camus, P.
- 238 Idiopathic Eosinophilic Pneumonias**
Lazor, R.; Cordier, J.-F.
- 250 Diffuse Alveolar Hemorrhage**
Olson, A.L.; Schwarz, M.I.
- 264 Pulmonary Langerhans' Cell Histiocytosis**
Harari, S.; Caminati, A.
- 275 Lymphangiomyomatosis**
Johnson, S.R.
- 285 Acquired Idiopathic Pulmonary Alveolar Proteinosis**
Costabel, U.; Bauer, P.C.; Guzman, J.
- 292 Bronchiolitis**
Poletti, V.; Casoni, G.; Zompatori, M.; Chilosi, M.
- 307 Lymphoproliferative Lung Disorders**
Poletti, V.; Zinzani, P.L.; Tomassetti, S.; Chilosi, M.

Special Considerations

- 324 Interstitial Lung Diseases in Children**
Clement, A.; Fauroux, B.
- 332 Lung Transplantation for Diffuse Parenchymal Lung Disease**
Irani, S.; Boehler, A.
- 341 Author Index**
- 342 Subject Index**

Foreword

The book series *Progress in Respiratory Research* was started in 1963 and is enjoying increasing success. Since I took over from my predecessor Prof. H. Herzog in 1997, my vision was to cover the whole area of thoracic medicine. In contrast to standard text books, however, this series aims at providing cutting-edge knowledge including the most recent advances in the field discussed. This necessitates three preconditions: top quality experts as volume and chapter authors, a strict enforcement of submission deadlines, and a fast printing process by the publisher. I am happy to say that all of these requirements have been fulfilled in this current 36th volume of *Progress in Respiratory Research* devoted to diffuse parenchymal lung disease (DPLD). The choice of the topic was made easy as none of the previous volumes have ever addressed DPLD, an important area in pulmonary medicine, where a lot of progress has been made during the last couple of years. It was therefore a timely topic to choose. The choice of terminology for the volume title was a deliberate one; the classic designation interstitial lung disease has been replaced by the more modern and more accurate term DPLD.

As usual, the most important task of the Editor-in-Chief after the choice of the topic of a volume was the choice of

the volume editor(s). I was fortunate enough to have the immediate support of three well-known experts in DPLD – Ulrich Costabel, Jim Egan and Ron Dubois – who shared the task of compiling the content and choosing the best possible authors to write the individual book chapters. As you the reader can easily see, the result has been a fantastic book covering all the important aspects and including the majority of leaders in DPLD at a global level. True to the vision of the book series, authors were instructed to include the latest references available at the time of writing. The book is aimed at all doctors from general practitioners to pulmonary physicians with a special interest in DPLD; there is something for everyone. For a more specific introduction of the various topics please see the preface by the volume editors.

My thanks go to the three editors as well as all the chapter authors, and, once again, to the editorial staff at the publishing house, S. Karger AG, Basel, Switzerland. The publisher has proved his quality once again by printing a high-quality book in the shortest possible time after receipt of the final manuscript, well done guys!

C.T. Bolliger
Cape Town

.....

Preface

Diffuse parenchymal lung diseases (DPLD) represent a large and heterogeneous group of disorders, many of them belonging to the category of orphan diseases. Our knowledge on DPLD has expanded greatly during the last decade. New insights into the pathogenesis and new techniques such as high-resolution CT scanning have made significant contributions to a better understanding of these less common disorders which remain an intellectual challenge to clinicians, radiologists and pathologists. DPLD comprise over 200 entities of known and unknown causes, with or without associated systemic disease, of acute or chronic onset, of indolent or rapidly progressive course, and wide variations in treatment response. The management of DPLD remains difficult, but correct diagnosis, appropriate treatment and a balanced assessment of prognosis are important. This issue of *Progress in Respiratory Research* aims to provide valuable information on the rapid advances in this field.


The first section covers general topics including the most recent classification system, the general diagnostic approach, and the clinical evaluation of the patient including radiology, histopathological patterns, and bronchoalveolar lavage findings. The concept of classification of DPLD has undergone significant change over recent years. The idiopathic interstitial pneumonias now comprise seven distinct diagnoses which have all been previously regarded as forms of idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Even the current classification is controversial, since disorders related to cigarette smoking such as DIP and RBILD are included without being truly idiopathic. In the diagnostic evaluation CT scanning can sometimes provide highly disease-specific information so that

surgical lung biopsy can be avoided. Diagnosis cannot, however, be based on imaging or histopathology alone, but needs precise clinical information, so that the necessity of a multidisciplinary clinical/radiological/pathological approach in making the final diagnosis has been emphasized.


Several chapters deal with the basic aspects of DPLD. Genetic factors that pre-dispose to DPLD and define clinical disease phenotypes have been characterized in sarcoidosis and systemic sclerosis, whereas this is far less advanced in idiopathic fibrosing lung diseases. The basics of granuloma formation, fibrogenesis in idiopathic pulmonary fibrosis, and mechanisms of vasculitis are highlighted. A special chapter addresses novel aspects of treatment for interstitial lung diseases with an emphasis on idiopathic pulmonary fibrosis.

A large section of the book is devoted to specific diseases, covering granulomatous disorders, idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias, collagen vascular diseases, drug-induced infiltrative lung disease, diffuse alveolar hemorrhage, and even rarer disease entities such as the eosinophilic pneumonias, Langerhans' cell histiocytosis, lymphangiomyomatosis and pulmonary alveolar proteinosis. Bronchiolitis and lymphoproliferative lung disorders are also included, since their clinical and radiological manifestations mimic diffuse parenchymal lung disease. The last two chapters are focused on DPLD in children and lung transplantation for end-stage fibrosis, two topics which deserve special consideration.


The editors have recruited international experts from the various disciplines involved in these disorders to



U. Costabel, Essen



R.M. du Bois, London



J.J. Egan, Dublin

contribute state-of-the-art reviews to this book. We hope that the readers will find it a helpful tool in the daily management of their patients with DPLD and an invaluable information source.

We thank Chris Bolliger for providing us with the opportunity to update a very exciting area in the field of lung diseases. We are grateful to S. Karger publishers for

being extremely supportive in getting the book published. Our special thanks go to the authors; we appreciate the high quality of their contributions and also their willingness to add the latest and hottest news to the bibliography of their chapters.

Ulrich Costabel, Roland M. du Bois, Jim J. Egan

